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Abstract
Background: Seasonal influenza is a viral disease whose annual epidemics are estimated to cause
three to five million cases of severe illness and 250,000 to 500,000 deaths worldwide. Vaccination
is the main strategy for primary prevention.
Methods: To assess the status of influenza vaccination in the Americas, influenza vaccination data
reported to the Pan American Health Organization (PAHO) through 2008 were analyzed.
Results: Thirty-five countries and territories administered influenza vaccine in their public health
sector, compared to 13 countries in 2004. Targeted risk groups varied. Sixteen countries reported
coverage among older adults, ranging from 21% to 100%; coverage data were not available for most
countries and targeted populations. Some tropical countries used the Northern Hemisphere
vaccine formulation and others used the Southern Hemisphere vaccine formulation. In 2008,
approximately 166.3 million doses of seasonal influenza vaccine were purchased in the Americas;
30 of 35 countries procured their vaccine through PAHO's Revolving Fund.
Conclusion: Since 2004 there has been rapid uptake of seasonal influenza vaccine in the Americas.
Challenges to fully implement influenza vaccination remain, including difficulties measuring coverage
rates, variable vaccine uptake, and limited surveillance and effectiveness data to guide decisions
regarding vaccine formulation and timing, especially in tropical countries.
Background
Influenza is a highly infectious viral disease transmitted
through respiratory droplets. Annual epidemics are esti-
mated to cause between three to five million cases of
severe illness and 250,000 to 500,000 deaths worldwide
[1,2]. Annual vaccination remains the main strategy for
primary prevention [3]. Seasonal influenza vaccines are
safe and provide a cost-effective tool to reduce the disease
burden [2,3]. The vaccine is composed of two influenza
type A viruses and one type B virus. Due to the constant
risk of antigenic drift-minor point mutations to the viral
genome-vaccines are reconfigured annually for both the
Northern and Southern Hemispheres [2]; the effectiveness
of the resulting vaccine depends on the degree of match
between vaccine viruses and circulating strains. Among
healthy populations under 65 years of age, the seasonal
influenza vaccine is 70-90% effective at preventing illness.
Among the elderly, the vaccine is 30-40% effective at pre-
venting disease, but 50-60% effective at preventing hospi-
talization, and 80% effective at preventing death [4].
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Decisions regarding annual vaccine composition for both
hemispheres are made by the World Health Organization
(WHO) based on viral surveillance data from WHO's Glo-
bal Influenza Surveillance Network (FluNet) [5]. The use
of either the Northern or Southern Hemisphere vaccine
depends on the pattern and timing of seasonal influenza
circulation. The epidemiology of influenza in temperate
regions of the Americas is well-described. In these regions
the peak influenza season occurs during the cold winter
months: November-March in the Northern Hemisphere
and April-September in the Southern Hemisphere [6]. The
epidemiology of seasonal influenza in tropical countries,
however, remains less well defined. In the tropics, influ-
enza transmission does not correspond to distinct peaks,
but is thought to occur on a year-round basis with epi-
demics typically occurring between the seasons in the
Northern and Southern Hemispheres [7].
In the Americas, Bermuda, Canada, Chile, and the United
States have utilized seasonal influenza vaccination for the
past several decades. Most other countries and territories
in Latin America and the Caribbean had not introduced
the vaccine into the public health sector until fairly
recently. In Latin America and the Caribbean, vaccines
offered through the public sector are purchased through
governmental funds and available to the public free of
charge. In 2003, during the 56th World Health Assembly,
the World Health Organization (WHO) recommended
nations to increase seasonal influenza vaccination cover-
age in all their high-risk groups. WHO posited the goal of
achieving 50% vaccination coverage in populations 65
years and older by 2006 and 75% coverage in this popu-
lation by 2010 [2,8]. In 2004, the Pan American Health
Organization's (PAHO) Technical Advisory Group on
Vaccine-preventable Diseases (TAG) expanded recom-
mendations for the Americas. PAHO's TAG is comprised
of eight immunization and vaccine experts that meet
biennially, in the presence of Member States' immuniza-
tion representatives, to provide recommendations on vac-
cination policy and strategies to improve countries'
vaccination efforts [9]. TAG recommended yearly sea-
sonal influenza vaccination for populations older than 60
years, chronically ill individuals, immunodeficient indi-
viduals, health professionals, and pregnant women in
their second trimester. In 2006, PAHO's TAG further
expanded routine vaccination to include children aged 6-
23 months [10].
The goal of this paper is to describe the status of seasonal
influenza vaccination in the Americas through December
2008, with a focus on Latin America and the Caribbean,
and to discuss future challenges for optimizing use of this
vaccine in the Region.
Methods
Influenza data reported by countries to the Comprehen-
sive Family Immunization Project (IM) at PAHO head-
quarters through December 2008 were compiled and
analyzed. Data were retrieved from seven sources: a PAHO
survey administered by IM to Member States in 2004, the
2006 WHO Global Influenza Survey, annual country
reports through the PAHO-WHO/UNICEF Joint Report-
ing Forms (JRF), information from PAHO's Revolving
Fund for Vaccine Procurement (RF) [11], publications of
governmental public health authorities [12,13], commu-
nications with PAHO immunization focal points in coun-
try offices, and a 2008 seasonal influenza questionnaire
(see additional file 1). For the purpose of this exercise,
information from the five islands of the Netherlands Anti-
lles was based on data received from the island of Bonaire.
Data from the French Departments in the Caribbean were
not included in this exercise as they do not routinely
report to PAHO.
The following information was collected: year of vaccine
introduction into the public and private sectors, vaccine
formulation used, timing of annual vaccination cam-
paigns, purchase of vaccine through the RF, criteria used
for vaccine introduction, the status of vaccine impact eval-
uations, population risk groups targeted for vaccination,
and the associated coverage rates. Vaccination coverage
rates in most Latin American and Caribbean countries are
calculated using administrative data, dividing the number
of doses of vaccine administered in the target age group by
the census projection for that group.
Results
Until 2004, 13 countries and territories had introduced
the seasonal influenza vaccine into their public health sys-
tems; of these countries, only Bermuda, Canada, Chile,
and the United States had been using the vaccine for mul-
tiple decades (Table 1). Every year subsequent to 2004,
substantial increases in the uptake of the seasonal influ-
enza vaccine have been observed. In 2005, five additional
countries and territories introduced the vaccine, followed
by seven, eight, and then two countries and territories in
2006, 2007, and 2008, respectively. As of December of
2008, 35 out of the 43 countries and territories in the
Americas included in this analysis had incorporated the
vaccine into their public health systems (Figure 1). The
use of the seasonal influenza vaccine through the private
sector in the Region, in some cases many years prior to its
introduction into the public sector, has been widespread,
but not quantified.
Countries and territories in the Americas target a wide
range of risk groups in their seasonal influenza vaccina-
tion recommendations. As of the end of 2008, 33 coun-
tries and territories were targeting older adults; of these,BMC Public Health 2009, 9:361 http://www.biomedcentral.com/1471-2458/9/361
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Table 1: Year of seasonal influenza vaccine introduction and population groups vaccinated in the Region of the Americas, 2008.
Coverage in older 
adults (%)
Other Risk Groups
Country Year of 
Vaccine 
Introductio
n
Children Older 
Adults
2006 2007 2008 Health 
workers
Chronic 
diseases
Pregnant 
Women
Poultry 
Workers
Other
Anguilla 2005 ✓A ✓
Antigua and 
Barbuda
2007 6-35 m ≥ 60 y
Argentina 1993 6-23 mA ≥ 65 y 50 ✓✓✓✓ ✓ B
Aruba NA
Bahamas 2005 6 m-5 y ≥ 65 y ✓✓✓
Barbados 2006 ✓C ✓✓ D
Belize 2008 6 m-23 m ≥ 65 y ✓✓
Bermuda 1970s 6 m-18 y ≥ 60 y 65E 60 ✓✓✓ ✓ F
Bolivia NA
Brazil 1999 ≥ 60 y 85.7 86.6 86.9 ✓✓ ✓ G
British 
Virgin 
Islands
2007 > 3 y ≥ 65 y ✓✓ H ✓I
Canada 1970s 6-23 m ≥ 65 y ✓✓✓✓ ✓ J
Cayman 
Islands
1990 6-23 m ≥ 50 y ✓✓✓ ✓ K
Chile 1975 6-23 m ≥ 60 y 89L 88.6 89.1 ✓✓✓✓ ✓ M
Colombia 2005 6-23 m ≥ 65 y ✓✓
Costa Rica 2004 6 m-8 yA ≥ 65 y ✓✓
Cuba 1998 < 24 yN ≥ 65 y 100 100 ✓✓ ✓
Dominica NA
Dominican 
Republic
2006 6-23 m ≥ 50 y ✓✓ ✓ ✓ O
Ecuador 2006 6-23 m ≥ 65 y 67 57.5 ✓
El Salvador 2004 6-23 m ≥ 60 y 99 92 100 ✓✓
Grenada 2007 6 m-5 y ≥ 60 y ✓✓
Guatemala 2007 ≥ 60 yP 100 ✓BMC Public Health 2009, 9:361 http://www.biomedcentral.com/1471-2458/9/361
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Guyana NA
Haiti NA
Honduras 2003 > 6 mA ≥ 60 yQ 90 83 ✓✓
Jamaica 2006 6 m-5 yA ≥ 60 yA ✓
Mexico 2004 6-35 m, 3-
9 yA
≥ 60 y 93.3 84.9 ✓✓
Montserrat 2007 < 9 y ✓✓ R
Netherlands 
Antilles 
(Bonaire)
2007 ✓A ≥ 65 y 100 100 100 ✓
Nicaragua 2007 6-23 mA ≥ 65 yA
Panama 2005 6-23 m ≥ 60 y 86.2 79 ✓✓ ✓
Paraguay 2005 6-23 m ≥ 60 y 74 73 ✓✓ ✓
Peru 2008 ✓
St. Kitts NA
St. Lucia 2006 ≥ 65 y ✓✓
St. Vincent NA
Suriname NA
Trinidad and 
Tobago
2007 6-23 m ≥ 60 y ✓✓ ✓ ✓ S
Turks and 
Caicos
2006 6 m-5 y ≥ 60 y ✓✓
USA 1940s 6 m-18 y ≥ 50 y 36 (50-64 y) 
65.6 (≥ 65 
y)T
✓✓✓ ✓ U
Uruguay 1996 6-23 m, > 
23 mA
≥ 65 y 29.2 31.1 ✓✓ ✓
Venezuela 2006 6-23 m ≥ 60 y 61.9 20.6 ✓✓
Source: Country and territory reports to PAHO.
A. With chronic disease; B. Essential services, security forces, and educators; C. The elderly in institutions; D. Military and front line staff; E. 
Coverage in 2006 is for populations ≥ 65 y; F. Others includes children on aspirin therapy, essential workers, travelers, close contacts or caregivers 
of individuals with chronic disease, and individuals living in crowded conditions; G. Indigenous population including population > 6 m and 
incarcerated populations; H. Renal dysfunction. I. Residents of nursing homes; J. Residents of nursing homes, those in contact with populations at 
high risk for influenza complications and those who provide essential community services; anyone else aged 2-64 years should be encouraged to get 
vaccinated; K. Police and fire, children < 6 m who are at high risk for complications and individuals caring for babies < 6 months; L. Those older than 
65; M. Egg producers; N. With asthma/diabetes; O. Public safety workers; P. In institutions; Q. ≥ 60 y in 2008 and ≥ 65 y in 2006 and 2007; R. High 
risk workers; S. National security; T. Coverage data are from the National Health Interview Survey (NHIS) for the 2006-2007 season; U. People in 
contact with those at high risk and all persons who want to reduce the risk of becoming ill with influenza or of transmitting it to others.
Table 1: Year of seasonal influenza vaccine introduction and population groups vaccinated in the Region of the Americas, 2008. BMC Public Health 2009, 9:361 http://www.biomedcentral.com/1471-2458/9/361
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Barbados and Guatemala targeted only those individuals
living in institutions. Anguilla, Jamaica, and Nicaragua
targeted older adults with chronic disease. Thirty-two
countries and territories targeted health workers. Twenty-
four countries and territories targeted individuals with
chronic disease, such as lung disease, cardiovascular dis-
eases, metabolic diseases, renal dysfunction, and immu-
nosuppressant diseases.
Twenty-nine countries and territories targeted children for
vaccination. Of these, 13 countries and territories recom-
mended vaccinating children aged 6-23 months; two
countries and territories recommended vaccinating chil-
dren aged 6-35 months; one territory recommended vac-
cinating children older than three years; three countries
and territories recommended targeting children aged 6
months-5 years; one territory recommended vaccinating
children aged up to nine years; Bermuda and the United
States recommended targeting all children aged 6 months-
18 years [13,14]. Argentina, Bonaire, Costa Rica, Cuba,
Honduras, Jamaica, and Nicaragua recommended only
targeting children with chronic disease.
Additional risk groups identified for prioritized influenza
vaccination included public safety workers, indigenous
populations, incarcerated individuals, and childcare pro-
viders (Table 1). Eleven countries and territories also
included poultry workers as targeted risk groups, while
seven countries and territories included pregnant women
(2nd trimester) in their vaccination campaigns.
Consistent seasonal influenza vaccine coverage data were
not widely available for most risk groups in the Region;
however, 2006 and 2007 coverage data for elderly adults
and children aged 6-23 months in selected countries can
be found in Figures 2 and 3. Of the 14 countries that
reported 2007 seasonal influenza vaccine coverage for the
elderly, 12 had surpassed WHO's target of 50% coverage
by 2006 and nine have already reached WHO's target of
75% coverage by 2010.
Twenty-six countries and territories utilized the Northern
Hemisphere formulation of influenza vaccine in their
yearly activities, whereas nine countries and territories
administered the Southern Hemisphere formulation. In
tropical areas of the Americas, both formulations were
used; in some cases, neighboring countries administered
different hemispheric formulations (Figure 4). Of note, in
Nicaragua, the Southern Hemisphere formulation became
available through the public sector beginning in 2007.
However, the Northern Hemisphere formulation is still
administered in the private sector, where it has been uti-
lized since 2005. Colombia initially introduced the
Northern Hemisphere formulation into the public health
sector in Bogotá in 2005. Since 2007, the country has
administered the Southern Hemisphere formulation
nationwide. This decision was made based on the timing
of disease peaks and the most recent vaccine formulation
available.
Countries and territories in the Americas identified several
criteria used to justify seasonal influenza vaccine intro-
duction. Seven countries and territories (Belize, Bonaire,
Brazil, Ecuador, Montserrat, Nicaragua, and Paraguay)
Number of countries and territories in the Americas with  public policies regarding seasonal influenza vaccination  (1970s-2008) Figure 1
Number of countries and territories in the Americas 
with public policies regarding seasonal influenza vac-
cination (1970s-2008). Note: Data not collected from the 
French Departments (French Guiana, Guadeloupe, and Mar-
tinique). Source: Country and territory reports to 
PAHO.
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Reported 2006 and 2007 seasonal influenza vaccination cov- erage among elderly populations in selected countries in  Latin America Figure 2
Reported 2006 and 2007 seasonal influenza vaccina-
tion coverage among elderly populations in selected 
countries in Latin America. Note: ≥ 65 years in Cuba, 
Chile (2006), Honduras; ≥ 60 years in Brazil, Chile (2007), El 
Salvador, Mexico, Panama, and Paraguay. Source: Country 
and territory reports to PAHO.
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identified morbidity and mortality as the main criteria
influencing vaccine introduction. The Cayman Islands
also identified morbidity and mortality as criteria, in addi-
tion to recommendations from PAHO and the United
States' Centers for Disease Control and Prevention
(CDC). Five countries (Argentina, Cuba, the Dominican
Republic, Grenada, and Venezuela) specified political
decisions as the influential force. In some countries and
territories, vaccine introduction was attributed to a com-
bination of factors. Eight countries (Chile, El Salvador,
Guatemala, Honduras, Mexico, Panama, Peru, and Uru-
guay) referenced morbidity and mortality in combination
with political decisions, and Colombia cited these two
factors plus cost-effectiveness studies as the rationale
behind vaccine introduction. In Costa Rica, seasonal
influenza vaccine administration began in 2004 after a
cost-effectiveness study was completed [15]. Of note, Bar-
bados indicated that the seasonal influenza vaccine was
introduced among health workers and front line staff in
preparation for pandemic influenza; however, uptake
Reported 2006 and 2007 seasonal influenza vaccine coverage  among children aged 6-23 months in selected countries in  Latin America Figure 3
Reported 2006 and 2007 seasonal influenza vaccine 
coverage among children aged 6-23 months in 
selected countries in Latin America. Source: Country 
and territory reports to PAHO.
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Formulation of seasonal influenza vaccine used in countries and territories of the Americas, 2008 Figure 4
Formulation of seasonal influenza vaccine used in countries and territories of the Americas, 2008. Source: Coun-
try and territory reports to PAHO.
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among health workers has been poor. For 2009, six coun-
tries reported plans to conduct national evaluations of the
impact of the seasonal influenza vaccine.
Of the 35 countries and territories that used seasonal
influenza vaccine in 2008, 30 purchased the vaccine
through PAHO's RF (Figure 5). The RF is a mechanism for
bulk purchase of vaccines and immunization supplies,
managed by PAHO since 1979, to serve Member States
[11,16]. In 2004, approximately 1.4 million doses of sea-
sonal influenza vaccine were purchased by countries
through the RF; in 2008 this figure had increased to
approximately 14.4 million doses (Figure 5). Outside of
the RF, in 2008, Brazil, Canada, Chile, Mexico, and the
United States purchased approximately 152.3 million
doses of seasonal influenza vaccine for a total of approxi-
mately 166.3 million doses of seasonal influenza vaccine
used in the Americas last year.
Discussion
As of December 2008, 35 of the 43 countries and territo-
ries of the Americas were recommending seasonal influ-
enza vaccination in the public sector, up from just 13 in
2004, representing a rapid uptake of the vaccine over the
last five years. Global progress outside the Region should
also be noted. In 2005, a study of 56 countries reported
rapid growth in influenza vaccination in the prior decade,
most notable in nations outside of North America and
Western Europe [17].
In this analysis, countries and territories identified the
morbidity and mortality caused by seasonal influenza and
the decision to introduce the vaccine at a political level as
the two most frequent reasons for seasonal influenza vac-
cine introduction. While an in-depth examination of
other factors influencing vaccine uptake was out of the
scope of this study, it is likely that the fairly rapid uptake
of influenza vaccine in the Region has been multi-facto-
rial. Fear of an influenza pandemic, the increased use of
the seasonal influenza vaccine in the private sector, the
actions of neighboring countries, and the influence of
PAHO's TAG recommendations likely played a role in
country and territory decisions to begin to administer the
vaccine in the public sector.
The groups targeted for seasonal influenza vaccination
varied between countries of the Americas, ranging from
only health workers and/or institutionalized older adults
in selected countries, to multiple groups at risk, such as
persons with chronic illness, children, pregnant women,
health care workers, and poultry and egg farmers. The
majority of those countries reporting influenza vaccine
coverage data among the elderly had surpassed WHO's
targets. Selected countries likely achieved such success
through large scale intensive national vaccination cam-
paigns, carried out over two to four week time periods.
Despite the selected coverage achievements in the Region,
efforts to improve influenza coverage monitoring among
all targeted populations will be essential to determine
what population groups are not being reached and to cre-
ate vaccination strategies to ensure better compliance.
Currently, in many countries, coverage rates for all tar-
geted population groups are not routinely available. Par-
ticular challenges exist when measuring coverage with the
vaccine, even among children. First, obtaining accurate
numerator and denominator data to calculate coverage
rates among target populations is often difficult as doses
administered in the public sector are more likely to be
recorded and consolidated then those given in the private
sector. Even in developed countries, there are difficulties
in obtaining definitive coverage figures [13,18]. Addition-
ally, for children, in order to build sufficient immunity,
individuals under nine years of age being vaccinated for
the first time need to receive two doses of the seasonal
influenza vaccine separated by at least a month [13]. This
requirement challenges the current health systems capac-
ity to calculate coverage data, as nationwide individual-
ized vaccination registries are not common and most
countries in Latin America and the Caribbean rely on
administrative data to calculate coverage.
Uptake of the seasonal influenza vaccine across all groups
at risk also needs to be improved. The seasonal influenza
vaccine is unique compared to other vaccines. To be effec-
Doses of adult and pediatric seasonal influenza vaccine pur- chased through the PAHO Revolving Fund (RF) for Vaccine  Procurement by year Figure 5
Doses of adult and pediatric seasonal influenza vac-
cine purchased through the PAHO Revolving Fund 
(RF) for Vaccine Procurement by year. Note: Brazil, 
Canada, Chile, Mexico, and the United States do not procure 
vaccine through the RF. Source: Country and territory 
reports to PAHO.
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tive, it must be administered annually, primarily through
time-limited campaigns, and target population groups
that are not necessarily accustomed to vaccination. Fur-
thermore, factors such as the public perception of influ-
enza risk and vaccine effectiveness may vary by year,
affecting vaccine uptake.
There was consistent use of the Northern or Southern
Hemisphere vaccine formulations in temperate countries
of the Americas, with the timing of vaccine campaigns
dependent on the annual vaccine production process. Suf-
ficient understanding of the viral circulation patterns in
temperate countries of the Region made the decisions
about vaccine formulation clear and uniform across
national borders. In contrast, there was a mix of formula-
tions and timing of annual campaigns in tropical coun-
tries. This may reflect the limited information available
regarding the epidemiology of influenza in tropical areas.
Recent studies have illustrated how seasonal influenza
epidemics appear to be impacted by the introduction of
new viral strains into a population [6], and how the initi-
ation of influenza A epidemics seem to follow latitudinal
gradients, moving from more tropical regions towards the
poles as the season progresses [6,19]. Nevertheless, in
order to better understand viral circulation in tropical
areas of the Americas, influenza viral surveillance needs to
be enhanced. Having better surveillance data will facilitate
decisions regarding the optimal timing of vaccination
campaigns and the best vaccine formulation to use. Of
note, since the advent of a Southern Hemisphere vaccine
formulation in 1999, this formulation has matched the
prior season's Northern Hemisphere formulation in 5 out
of eleven years. Advances in viral surveillance in tropical
areas will help avoid the current reliance on information
generated from isolated studies. In the Americas, work in
this area has already begun through a cooperative agree-
ment between PAHO and CDC to strengthen influenza
surveillance in the Region [20]. For children, some coun-
tries in the Americas are integrating sentinel influenza sur-
veillance with existing pneumonia surveillance systems.
Countries that have not introduced the seasonal influenza
vaccine would benefit from evaluating local influenza epi-
demiology and conducting cost-effectiveness studies in
order to develop the most informed, evidence-based pol-
icies. To this end, PAHO's ProVac initiative has been
established to help countries conduct such evaluations to
make evidence-based decisions [21]. Countries already
administering the seasonal influenza vaccine may benefit
from evaluating the impact of the vaccine's use and, more
specifically, the formulation administered. Such research
would be especially informative if completed in large
countries, such as Brazil, that utilize one vaccine formula-
tion, but have both tropical and subtropical zones and
varying influenza disease peaks [19]. Studies in Brazil sug-
gest that the Southern Hemisphere vaccine formulation,
currently utilized nationwide, may not have a significant
impact in the reduction of morbidity and mortality
among elderly populations in northern areas of the coun-
try (Brazil Ministry of Health unpublished data). Disease
cases in Northern Brazil peak from March to May; ideally
vaccination here would occur in February, which is prior
to the availability of the Southern Hemisphere vaccine
formulation [22]. Studies analyzing the impact of using
the vaccine formulation available prior to disease peaks
(Northern Hemisphere) in these areas would be of inter-
est. Furthermore, research in neighboring countries with
similar climates, but in which different vaccine formula-
tions are currently administered, would also be informa-
tive.
The annual supply of seasonal influenza vaccine needs to
meet the accelerated demand. In order to increase produc-
tion capacity for seasonal influenza vaccine in the Ameri-
cas, Brazil and Mexico are currently in the process of
establishing influenza vaccine production facilities
through technology transfer agreements brokered
through the WHO [23]. This will be particularly impor-
tant as countries expand their recommended populations
groups and age ranges targeted for seasonal influenza vac-
cination, as the United States has done with the recom-
mended age for childhood vaccination, moving from six
months-23 months to six months-five years in 2006, and
to six months-18 years in 2008 [13,14].
This paper aims to provide a general overview of the use
of seasonal influenza vaccine in the Region of the Ameri-
cas. This study has several limitations, including the fol-
lowing: data were limited for some countries and
territories and information sources did not provide in-
depth evaluation of the specific reasons taken for vaccine
introduction. Additionally, as is done for most reporting
of vaccine coverage rates for childhood diseases, seasonal
influenza coverage rates reported were calculated using
administrative data, which have inherent limitations. The
main findings, however, are solid: while some countries
in the Americas have been utilizing seasonal influenza
vaccine for many decades, a rapid uptake of the vaccine
has occurred in the last five years, the targeted groups vary,
there is a mix of formulations used in tropical areas, and
coverage data is limited and may need to be further vali-
dated. In-depth studies to understand the factors for vac-
cine introduction in more detail would also be useful.
Conclusion
Since 2004 there has been rapid uptake of seasonal influ-
enza vaccine in the Americas. However, countries con-
tinue to face challenges to fully implement influenza
vaccination in populations at risk. Strategies are needed to
expand vaccination uptake, improve coverage monitor-BMC Public Health 2009, 9:361 http://www.biomedcentral.com/1471-2458/9/361
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ing, and enhance surveillance. Effectiveness evaluations
will be crucial to better understand the impact of seasonal
influenza vaccination in countries of the Americas.
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